Drug Profile


Alternative Names: 221149; GSK-221149; GSK-221149A

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Indenes; Morpholines; Oxazoles; Piperazines; Small molecules; Tocolytics
  • Mechanism of Action Oxytocin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Preterm labour

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 20 Oct 2017 GlaxoSmithKline terminates a phase III trial in Preterm labour in Israel, Belgium, Germany, South Korea, Italy, Spain, Sweden, France, Mexico due to feasibility of recruiting the study in a timely manner (IV) (NCT02292771)
  • 28 Jun 2017 GlaxoSmithKline terminates phase III trial in Preterm labour (In adolescents, In adults) in USA (IV) (NCT02377466)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top